End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 ZAR | -2.46% | -0.95% | -37.40% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- With a P/E ratio at 10.95 for the current year and 9.14 for next year, earnings multiples are highly attractive compared with competitors.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-37.40% | 887M | A | ||
+26.40% | 88.08B | C+ | ||
-24.06% | 75.32B | B- | ||
+3.45% | 28.19B | C+ | ||
+7.16% | 17.78B | A- | ||
-12.35% | 16.64B | B | ||
+1.36% | 15.64B | A- | ||
+81.12% | 13.81B | C- | ||
-26.67% | 13.01B | - | - | |
+23.10% | 12.43B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LHC Stock
- Ratings Life Healthcare Group Holdings Limited